Healthcare Master Fun Broadfin Sells 76,000 Shares of Recro Pharma Inc (REPH) Stock

Recro Pharma Inc (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 76,000 shares of the company’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $9.87, for a total transaction of $750,120.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Wednesday, December 13th, Healthcare Master Fun Broadfin sold 93,237 shares of Recro Pharma stock. The shares were sold at an average price of $9.86, for a total transaction of $919,316.82.
  • On Tuesday, December 5th, Healthcare Master Fun Broadfin sold 100,000 shares of Recro Pharma stock. The shares were sold at an average price of $10.00, for a total transaction of $1,000,000.00.
  • On Tuesday, November 28th, Healthcare Master Fun Broadfin sold 47,549 shares of Recro Pharma stock. The shares were sold at an average price of $9.64, for a total transaction of $458,372.36.
  • On Thursday, November 30th, Healthcare Master Fun Broadfin sold 222,616 shares of Recro Pharma stock. The shares were sold at an average price of $9.58, for a total transaction of $2,132,661.28.
  • On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The shares were sold at an average price of $9.50, for a total transaction of $973,180.00.
  • On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The shares were sold at an average price of $9.45, for a total transaction of $1,627,365.60.

Recro Pharma Inc (REPH) traded down $0.04 during trading hours on Friday, reaching $9.75. 173,100 shares of the company’s stock traded hands, compared to its average volume of 121,069. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma Inc has a 12 month low of $5.81 and a 12 month high of $10.59.

Several brokerages recently issued reports on REPH. Zacks Investment Research cut shares of Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recro Pharma in a research note on Friday, October 27th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $11.65.

Large investors have recently bought and sold shares of the business. Janney Montgomery Scott LLC boosted its holdings in Recro Pharma by 76.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock valued at $155,000 after purchasing an additional 9,600 shares during the last quarter. Teachers Advisors LLC acquired a new position in Recro Pharma in the 2nd quarter valued at about $162,000. California State Teachers Retirement System acquired a new position in Recro Pharma in the 2nd quarter valued at about $169,000. JPMorgan Chase & Co. boosted its holdings in Recro Pharma by 183.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after purchasing an additional 14,098 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. acquired a new position in Recro Pharma in the 2nd quarter valued at about $215,000. Institutional investors own 61.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Healthcare Master Fun Broadfin Sells 76,000 Shares of Recro Pharma Inc (REPH) Stock” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.com-unik.info/2017/12/22/healthcare-master-fun-broadfin-sells-76000-shares-of-recro-pharma-inc-reph-stock.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit